Literature DB >> 9387969

Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin.

E Martínez-Moragón1, J Aparicio, M C Rogado, J Sanchis, F Sanchis, V Gil-Suay.   

Abstract

Malignant pleural effusions are commonly managed with tube thoracostomy drainage followed by chemical pleurodesis. Both tetracycline and bleomycin have been shown to be effective for intrapleural instillation, although neither agent has definitively proved advantages over the other. The aim of the present study was to compare these two agents in terms of response rate and toxicity profile. A prospective, randomized trial was carried out in a single centre. Between May 1993 and January 1996, 62 evaluable patients with proved malignant pleural effusion were allocated to receive either intrapleural tetracycline (1.5 g) or bleomycin (60 mg) after the same drainage procedure. Demographic, clinical and fluid parameter data were comparable in both groups. Response was evaluated at 1, 3 and 6 months after pleurodesis. Mean survival and time to relapse did not differ between the two groups. No statistically significant differences were found in terms of efficacy at each evaluation time. Overall, 16 (52%) and 20 (64%) patients had a recurrence of pleural effusion during follow-up in the tetracycline and bleomycin arms, respectively. Fever was most common in bleomycin-treated patients (p=0.024) while pain was most frequent in the tetracycline arm (nonsignificant). Since no study agent was superior to the other in this trial, we suggest that economic costs, drug availability and medical skill should be considered in the choice of a sclerosing agent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9387969     DOI: 10.1183/09031936.97.10102383

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  BTS guidelines for the management of malignant pleural effusions.

Authors:  G Antunes; E Neville; J Duffy; N Ali
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Efficacy and safety of Viscum album extract (Helixor-M) to treat malignant pleural effusion in patients with lung cancer.

Authors:  Yun-Gyoo Lee; Ina Jung; Dong-Hoe Koo; Du-Young Kang; Tae Yoon Oh; Sukjoong Oh; Seung-Sei Lee
Journal:  Support Care Cancer       Date:  2018-09-14       Impact factor: 3.603

3.  Bleomycin in the treatment of 50 cases with malignant pleural effusion.

Authors:  Novin Nikbakhsh; Ali Pourhasan Amiri; Danial Hoseinzadeh
Journal:  Caspian J Intern Med       Date:  2011

Review 4.  Malignant pleural effusion and algorithm management.

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Nikolaos Machairiotis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Eirini Terzi; Bojan Zaric; Haidong Huang; Lutz Freitag; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

Review 5.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Amelia O Clive; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell
Journal:  Cochrane Database Syst Rev       Date:  2016-05-08

6.  An update in the management of malignant pleural effusion.

Authors:  Dk Muduly; Svs Deo; Ts Subi; Aa Kallianpur; Nk Shukla
Journal:  Indian J Palliat Care       Date:  2011-05

7.  Interventions for the management of malignant pleural effusions: a network meta-analysis.

Authors:  Alexandra Dipper; Hayley E Jones; Rahul Bhatnagar; Nancy J Preston; Nick Maskell; Amelia O Clive
Journal:  Cochrane Database Syst Rev       Date:  2020-04-21

8.  Efficacy and Safety of Povidone-iodine Pleurodesis in Malignant Pleural Effusions.

Authors:  Hadi Kahrom; Manouchehr Aghajanzadeh; Mohammad Reza Asgari; Mahdi Kahrom
Journal:  Indian J Palliat Care       Date:  2017 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.